The medicinal mushroom Ganoderma lucidum(GL,Reishi or Lingzhi)exhibits an inhibitory effect on cancers.However,the underlying mechanism of the antitumor activity of GL is not fully understood.In this study,we characte...The medicinal mushroom Ganoderma lucidum(GL,Reishi or Lingzhi)exhibits an inhibitory effect on cancers.However,the underlying mechanism of the antitumor activity of GL is not fully understood.In this study,we characterized the gene networks regulated by a commercial product of GL containing a mixture of spores and fruiting bodies namely“GLSF”,in colorectal carcinoma.We found that in vitro co-administration of GLSF extract at non-toxic concentrations significantly potentiated growth inhibition and apoptosis induced by paclitaxel in CT26 and HCT-15 cells.GLSF inhibited NF-κB promoter activity in HEK-293 cells but did not affect the function of P-glycoprotein in K562/DOX cells.Furthermore,we found that when mice were fed a modified diet containing GLSF for 1 month prior to the CT26 tumor cell inoculation,GLSF alone or combined with Nab-paclitaxel markedly suppressed tumor growth and induced apoptosis.RNA-seq analysis of tumor tissues derived from GLSF-treated mice identified 53 differentially expressed genes compared to normal tissues.Many of the GLSFdown-regulated geneswere involved in NF-κB-regulated inflammation pathways,such as IL-1β,IL-11 and Cox-2.Pathway enrichment analysis suggested that several inflammatory pathways involving leukocytemigration and adhesion were most affected by the treatment.Upstream analysis predicted activation of multiple tumor suppressors such asα-catenin and TP53 and inhibition of critical inflammatory mediators.“Cancer”was the major significantly inhibited biological effect of GLSF treatment.These results demonstrate that GLSF can improve the therapeutic outcome for colorectal cancer through a mechanism involving suppression of NF-κB-regulated inflammation and carcinogenesis.展开更多
文摘The medicinal mushroom Ganoderma lucidum(GL,Reishi or Lingzhi)exhibits an inhibitory effect on cancers.However,the underlying mechanism of the antitumor activity of GL is not fully understood.In this study,we characterized the gene networks regulated by a commercial product of GL containing a mixture of spores and fruiting bodies namely“GLSF”,in colorectal carcinoma.We found that in vitro co-administration of GLSF extract at non-toxic concentrations significantly potentiated growth inhibition and apoptosis induced by paclitaxel in CT26 and HCT-15 cells.GLSF inhibited NF-κB promoter activity in HEK-293 cells but did not affect the function of P-glycoprotein in K562/DOX cells.Furthermore,we found that when mice were fed a modified diet containing GLSF for 1 month prior to the CT26 tumor cell inoculation,GLSF alone or combined with Nab-paclitaxel markedly suppressed tumor growth and induced apoptosis.RNA-seq analysis of tumor tissues derived from GLSF-treated mice identified 53 differentially expressed genes compared to normal tissues.Many of the GLSFdown-regulated geneswere involved in NF-κB-regulated inflammation pathways,such as IL-1β,IL-11 and Cox-2.Pathway enrichment analysis suggested that several inflammatory pathways involving leukocytemigration and adhesion were most affected by the treatment.Upstream analysis predicted activation of multiple tumor suppressors such asα-catenin and TP53 and inhibition of critical inflammatory mediators.“Cancer”was the major significantly inhibited biological effect of GLSF treatment.These results demonstrate that GLSF can improve the therapeutic outcome for colorectal cancer through a mechanism involving suppression of NF-κB-regulated inflammation and carcinogenesis.
